Optimal blood sampling time windows for parameter estimation using a population approach: Design of a phase II clinical trial

Research output: Contribution to journalArticle

  • External authors:
  • Marylore Chenel
  • Vincent Duval
  • Christian Laveille
  • Roeline Jochemsen

Abstract

The objective of this paper is to determine optimal blood sampling time windows for the estimation of pharmacokinetic (PK) parameters by a population approach within the clinical constraints. A population PK model was developed to describe a reference phase II PK dataset. Using this model and the parameter estimates, D-optimal sampling times were determined by optimising the determinant of the population Fisher information matrix (PFIM) using PFIM_ _M 1.2 and the modified Fedorov exchange algorithm. Optimal sampling time windows were then determined by allowing the D-optimal windows design to result in a specified level of efficiency when compared to the fixed-times D-optimal design. The best results were obtained when K a and IIV on K a were fixed. Windows were determined using this approach assuming 90% level of efficiency and uniform sample distribution. Four optimal sampling time windows were determined as follow: at trough between 22 h and new drug administration; between 2 and 4 h after dose for all patients; and for 1/3 of the patients only 2 sampling time windows between 4 and 10 h after dose, equal to [4 h-5 h 05] and [9 h 10-10 h]. This work permitted the determination of an optimal design, with suitable sampling time windows which was then evaluated by simulations. The sampling time windows will be used to define the sampling schedule in a prospective phase II study. © 2005 Springer Science+Business Media, Inc.

Bibliographical metadata

Original languageEnglish
Pages (from-to)737-756
Number of pages19
JournalJournal of pharmacokinetics and pharmacodynamics
Volume32
Issue number5-6
DOIs
Publication statusPublished - Dec 2005